Spots Global Cancer Trial Database for ctcl
Every month we try and update this database with for ctcl cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Safety Study of SGN-35T in Adults With Advanced Cancers | NCT06120504 | Lymphoma, T-Cel... Hodgkin Disease Lymphoma, T-Cel... Lymphoma, Large... Lymphoma, Large... Lymphoma, Non-H... | SGN-35T | 18 Years - | Seagen Inc. | |
| Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome | NCT00047060 | Mycosis Fungoid... Sezary Syndrome | A matched perip... cyclosporine fludarabine Campath | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma | NCT03952078 | T-cell Lymphoma | CPI-818 | 18 Years - | Corvus Pharmaceuticals, Inc. | |
| A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL | NCT03239392 | LGL Leukemia CTCL | BNZ132-1-40 | 18 Years - | Bioniz Therapeutics | |
| CD5789 in Early Cutaneous T-Cell Lymphoma (CTCL) | NCT01804335 | Lymphoma | CD5789 0.01% Cr... | 18 Years - | M.D. Anderson Cancer Center | |
| Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma | NCT02213861 | Cutaneous T-Cel... | SHAPE | 18 Years - | TetraLogic Pharmaceuticals | |
| Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome | NCT04256018 | Sezary Syndrome Mycosis Fungoid... | Mogamulizumab LD TSEBT | 18 Years - | Stanford University | |
| Ritlecitinib in CTCL | NCT05879458 | CTCL Mycosis Fungoid... Sezary Syndrome | Ritlecitinib | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL | NCT03239392 | LGL Leukemia CTCL | BNZ132-1-40 | 18 Years - | Bioniz Therapeutics | |
| Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides | NCT02943642 | Mycosis Fungoid... | A-dmDT390-bisFv... Vorinostat | 18 Years - | Angimmune LLC | |
| Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL) | NCT00490776 | Cutaneous T-Cel... | Panobinostat | 18 Years - | Novartis | |
| A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL | NCT05138458 | Lymphoma, T-Cel... Lymphoma, T-Cel... Mycosis Fungoid... Adoptive Cellul... Cell Therapy | MT-101 MT-101 + Condit... | 18 Years - | Myeloid Therapeutics | |
| Ritlecitinib in CTCL | NCT05879458 | CTCL Mycosis Fungoid... Sezary Syndrome | Ritlecitinib | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma | NCT01445340 | Mycosis Fungoid... Cutaneous T-Cel... Neoplasms | Romidepsin (FR9... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma | NCT05079282 | Relapsed or Ref... | ONO-4685 | 18 Years - | Ono Pharmaceutical Co. Ltd | |
| CD5789 in Early Cutaneous T-Cell Lymphoma (CTCL) | NCT01804335 | Lymphoma | CD5789 0.01% Cr... | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL | NCT03240211 | PTCL CTCL | Pembrolizumab Pralatrexate Decitabine | 18 Years - 90 Years | University of Virginia | |
| Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma | NCT02341209 | Cutaneous T-cel... Mycosis Fungoid... Sezary Syndrome | Doxycycline mon... | 18 Years - | Rochester General Hospital | |
| A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas | NCT00274651 | Cutaneous T-Cel... Peripheral T-Ce... Non-Hodgkin's L... | belinostat | 18 Years - | Valerio Therapeutics | |
| Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders | NCT03601819 | Lymphoma, T-Cel... Lymphoma, T-Cel... Chronic Lymphoc... Lymphoprolifera... Waldenstrom Mac... Lymphoplasmacyt... Mantle Cell Lym... | Pacritinib | 18 Years - | University of Michigan Rogel Cancer Center | |
| A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | NCT02643303 | Head and Neck S... Breast Cancer Sarcoma Merkel Cell Car... Cutaneous T-Cel... Melanoma Renal Cancer Bladder Cancer Prostate Cancer Testicular Canc... Solid Tumor | Durvalumab Tremelimumab Poly-ICLC | 18 Years - | Ludwig Institute for Cancer Research | |
| Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas | NCT02503423 | Solid Tumors Lymphoma | ASTX660 | 18 Years - | Astex Pharmaceuticals, Inc. | |
| Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma | NCT00888927 | Peripheral T-Ce... | KW-0761 | 18 Years - | Kyowa Kirin Co., Ltd. | |
| AFM13 in Relapsed/Refractory Cutaneous Lymphomas | NCT03192202 | Lymphoma, T-Cel... | AFM13 | 18 Years - | Columbia University | |
| Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma | NCT02213861 | Cutaneous T-Cel... | SHAPE | 18 Years - | TetraLogic Pharmaceuticals | |
| Mechlorethamine Induced Contact Dermatitis Avoidance Study | NCT03380026 | Cutaneous T-cel... Cutaneous T-cel... Mycosis Fungoid... Folliculotropic... Granulomatous S... Syringotropic M... Mycosis Fungoid... Transformed Myc... | Triamcinolone Valchlor 0.016 ... | 18 Years - | Rochester Skin Lymphoma Medical Group, PLLC | |
| Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma | NCT00506129 | Lymphoma Disorder Relate... | Fludarabine Melphalan Allogeneic Tran... Thymoglobulin | - 70 Years | M.D. Anderson Cancer Center | |
| Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma | NCT00506129 | Lymphoma Disorder Relate... | Fludarabine Melphalan Allogeneic Tran... Thymoglobulin | - 70 Years | M.D. Anderson Cancer Center | |
| A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL) | NCT04171791 | CTCL | ABT-199 (veneto... | 18 Years - | Yale University | |
| Recalcitrant Pruritus in Cutaneous T-Cell Lymphoma | NCT00863395 | Cutaneous T-Cel... | skin biopsy | 18 Years - | University of Minnesota | |
| Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma | NCT00506129 | Lymphoma Disorder Relate... | Fludarabine Melphalan Allogeneic Tran... Thymoglobulin | - 70 Years | M.D. Anderson Cancer Center | |
| Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL) | NCT01843998 | Cutaneous T-cel... | Sirolimus 0.1% ... | 18 Years - | Medical College of Wisconsin | |
| A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) | NCT03292406 | Cutaneous T Cel... | Placebo CD11301 0.03% CD11301 0.06% | 18 Years - | Galderma R&D | |
| Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma | NCT02567656 | Lymphoma, T-Cel... Lymphoma, T-Cel... | RP6530 | 18 Years - | Rhizen Pharmaceuticals SA | |
| Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL) | NCT01433731 | Lymphoma, T-Cel... | placebo for SHA... SHAPE (SHP-141)... SHAPE (SHP-141)... SHAPE (SHP-141)... | 18 Years - | TetraLogic Pharmaceuticals | |
| Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL | NCT02811783 | Mycosis Fungoid... Lymphoma, T-Cel... Sézary Syndrome | Naloxone Hydroc... Placebo Lotion | 21 Years - | Elorac, Inc. | |
| NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT) | NCT02542124 | Cutaneous T Cel... Mycosis Fungoid... Sézary Syndrome | NM-IL-12 and TS... | 18 Years - | Neumedicines Inc. | |
| Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma | NCT02301494 | Mycosis Fungoid... | 3.75% Imiquimod... 0.1% Fluocinoni... | 18 Years - | Rochester General Hospital | |
| Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL | NCT00178841 | Cutaneous T-cel... Mycosis Fungoid... Sezary Syndrome | Rosiglitazone a... | 18 Years - | Vanderbilt University | |
| FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) | NCT02448381 | Cutaneous T-Cel... | SGX301 (synthet... Placebo | 18 Years - | Soligenix | |
| FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) | NCT02448381 | Cutaneous T-Cel... | SGX301 (synthet... Placebo | 18 Years - | Soligenix | |
| Skin Barrier and Microbiome of CTCL Patients | NCT05827107 | Lymphoma, T-Cel... | 18 Years - | Centre for Human Drug Research, Netherlands | ||
| FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) | NCT02448381 | Cutaneous T-Cel... | SGX301 (synthet... Placebo | 18 Years - | Soligenix | |
| Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL) | NCT01007448 | Refractory Cuta... | Bexarotene | 18 Years - | Bausch Health Americas, Inc. | |
| Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL) | NCT02192021 | Cutaneous T Cel... | Micro needle ar... | 18 Years - | University of Pittsburgh | |
| Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001 | NCT01226472 | Peripheral T-ce... Cutaneous T-cel... | KW-0761 | 18 Years - | Kyowa Kirin Co., Ltd. | |
| FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) | NCT02448381 | Cutaneous T-Cel... | SGX301 (synthet... Placebo | 18 Years - | Soligenix | |
| Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma | NCT02314247 | Peripheral T-ce... Cutaneous T-cel... | Selinexor | 18 Years - | Karyopharm Therapeutics Inc | |
| A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) | NCT03292406 | Cutaneous T Cel... | Placebo CD11301 0.03% CD11301 0.06% | 18 Years - | Galderma R&D | |
| A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | NCT02643303 | Head and Neck S... Breast Cancer Sarcoma Merkel Cell Car... Cutaneous T-Cel... Melanoma Renal Cancer Bladder Cancer Prostate Cancer Testicular Canc... Solid Tumor | Durvalumab Tremelimumab Poly-ICLC | 18 Years - | Ludwig Institute for Cancer Research | |
| A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL | NCT05138458 | Lymphoma, T-Cel... Lymphoma, T-Cel... Mycosis Fungoid... Adoptive Cellul... Cell Therapy | MT-101 MT-101 + Condit... | 18 Years - | Myeloid Therapeutics | |
| Recalcitrant Pruritus in Cutaneous T-Cell Lymphoma | NCT00863395 | Cutaneous T-Cel... | skin biopsy | 18 Years - | University of Minnesota | |
| Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma | NCT01445340 | Mycosis Fungoid... Cutaneous T-Cel... Neoplasms | Romidepsin (FR9... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma | NCT00476554 | Cutaneous T-cel... | Sapacitabine | 18 Years - | Cyclacel Pharmaceuticals, Inc. | |
| A Safety Study of SGN-35T in Adults With Advanced Cancers | NCT06120504 | Lymphoma, T-Cel... Hodgkin Disease Lymphoma, T-Cel... Lymphoma, Large... Lymphoma, Large... Lymphoma, Non-H... | SGN-35T | 18 Years - | Seagen Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
